Complaint Handling, Recall Records and Device-Level Traceability

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

South Africa’s vigilance system is built on verifiable records: adverse events are submitted on form GLF-MD-11A with one form per device; Field Safety Corrective Actions (FSCAs) require a complete initial report and provable delivery records; and upstream of all of this sit the complaint handling and recall records. Complaints are the first source of reportable events, and recalls are the last resort of risk control — the quality of the records for both directly determines the outcome of SAHPRA inspections and vigilance investigations. A company whose complaint file, recall file and vigilance submissions tell a consistent story, indexed by device and batch rather than by customer or order, will move through an inspection with far less friction than one whose records must be reconstructed after the fact.

2. Legal basis

InstrumentReference numberPublication dateProvisions
SAHPRA guidance on vigilance: reporting of adverse events for medical devicesSAHPGL-MD-03 v413 December 2024Full text; Annex 1 decision tree; Annex 2 exemption rules; report types (initial, follow-up, final)
SAHPRA FAQs on Medical Device Adverse Events and FSCAFAQsCurrent version, verified as of 29 October 2026One form per device; FSCA initial report content; delivery methods
Regulations relating to Medical Devices and In Vitro Diagnostic Medical Devices (IVDs)Government Gazette No. 40480, Notice No. 1515Published on 9 December 2016Regulation 17 (adverse event reporting and vigilance); Regulation 18 (investigation); Regulation 19 (offences and penalties)
Medical device adverse event report formGLF-MD-11ACurrent version, verified as of 29 October 2026Full form text

3. Expert insights

Insight one: the one-form-per-device rule dictates that records must be organised by device. SAHPRA requires adverse event reports to be submitted with one form per device. This means the company’s complaint and event register must be indexed by device, model and batch, not by customer or purchase order. A register organised by customer requires extensive splitting and reassembly at submission time, which is one of the most common sources of delay, and delay is precisely what the reporting timelines leave no room for.

Insight two: a complaint is not an adverse event, but complaints are the entry point for events. The scope of a complaint is broader than that of an adverse event, covering quality, logistics and service issues as well. Companies must have an explicit decision rule for which categories of complaints are escalated into adverse event reports. That rule should be written into the SOP, applied with a recorded rationale for each complaint, rather than resting on the personal judgement of whichever staff member happens to open the file.

Insight three: Regulation 18 provides the basis for SAHPRA’s investigative powers. The 2016 Regulations contain Regulation 18 (Investigation), placed next to Regulation 19 (Offences and penalties). This arrangement shows that records are not merely an internal management tool but the first source of evidence when SAHPRA opens an investigation. Missing records make the subsequent handling materially worse, because the absence of documentation is itself interpreted against the company rather than treated as a neutral fact.

Insight four: recall records must prove scope and effectiveness. The FSCA initial report requires a list of affected countries, product codes and batch numbers, and an explanation of why other batches are not affected. This demands that the company’s traceability reaches at least the granularity of locating distribution flows by batch number — which is the real capability requirement that the South African vigilance system places on companies. Anything less turns a recall from a controlled exercise into a scramble.

Insight five: the exemption decision itself must also leave a trail. The four exemption categories in Annex 2 of SAHPGL-MD-03 give companies room not to report, but the exemption decision must be supported by a documented rationale. If SAHPRA later questions a specific event, the company must be able to explain why it was judged exempt at the time. An exemption without a record is no exemption at all.

4. Practical recommendations

  1. Organise the register by device and batch: matching the one-form-per-device requirement.
  2. Write the complaint-to-adverse-event escalation rule into the SOP: and keep the decision record for each case.
  3. Use recall records to prove scope and effectiveness: batch flows, notifications and retrieval outcomes.
  4. Document exemption decisions: record the rationale and the responsible person.
  5. Retain FSCA delivery evidence: e-mail receipts, registered mail, visit records.
  6. Run periodic record completeness self-checks: simulate the SAHPRA inspection perspective.

5. Verification checklist

  • □ The complaint and event register is organised by device and batch
  • □ Submissions are made on GLF-MD-11A with one form per device
  • □ The complaint-to-adverse-event escalation rule is in the SOP with decision records retained
  • □ Traceability reaches the granularity of locating flows by batch number
  • □ Recall records include batch flows, notifications and retrieval outcomes
  • □ Exemption decisions are documented with rationale and responsible person
  • □ FSCA delivery evidence is archived (4 categories of channels)
  • □ A periodic record completeness self-check mechanism is in place

Regulatory information verified as of 29 October 2026. The regulations, guidance and effective dates described in this article are limited to the official sources listed in the legal basis section above as published on that date; where official documents have been updated, the most recently published version prevails.

  • Local resources in South Africa: GRZAN assists manufacturers from the Chinese mainland and other markets with SAHPRA medical device establishment licence (MDEL) applications and product registration preparation, including authorised representative (AR) scheme design, ISO 13485 certification pathway planning and CAB selection, GMDN coding and classification determination, technical documentation, and the setup of vigilance and adverse event notification mechanisms.
  • Service capabilities: product attribute determination and risk classification (Class A, B, C, D), establishment licence applications and renewals, reliance pathway argumentation, technical documentation and essential principles conformity argumentation, labelling and instructions for use localisation in English, and support for post-market vigilance and annual compliance submissions.
  • Contact: info@grzanglobal.com; hito.lin@grzan.cn; website www.grzan.cn.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail